Trial
NCT06056310
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Merck KGaA, Darmstadt, Germany
Condition
Head and Neck Cancer
Intervention
Xevinapant
Why stopped
No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-29